Building the Life Sciences Workforce of the Future

Posted on Fri/30/JanuaryFri/30/January by AZBio

The Life Sciences Workforce Collaborative (LSWC) launched its first LSWC Best Workforce Strategies Roundtable on January 30, 2026 with opening remarks from Caitlin Frazer, Executive Director of the National Security Commission on Emerging Biotechnology (NSCEB).Continue reading→

Tracking U.S. Biopharma Investment: New Resources Detail State-by-State Impact

Posted on Thu/29/JanuarySun/1/February by AZBio

America’s biopharmaceutical sector is delivering unprecedented economic impact across the nation. Since January 2025, companies have committed more than $582 billion to bolster U.S. research and development, expand manufacturing and create jobs in communities nationwide.From cutting-edge manufacturing facilities in the South to next-generation research hubs in the Mid-Atlantic, the life sciences industry is driving local economic growth, creating high-skill jobs and ensuring Americans have faster access to breakthrough medicines.Continue reading→

Breakthru Medicine emerges from stealth with $60M Series A for cancer drug development

Posted on Thu/29/JanuaryWed/28/January by AZBio

Phoenix, AZ, January 29, 2026 (Globe Newswire): Breakthru Medicine emerges from stealth mode with the close of a $60M Series A financing round following a prior undisclosed seed round.

Breakthru was founded by biotech industry veterans Steve Potts, PhD, Mark Mulvihill, PhD, and Brian Barnett, MD, to deliver disruptive therapeutic modalities to cancer patients to address major unmet medical needs.Continue reading→

BioLab Holdings Announces Investment in Advanced Synthetic Antimicrobial -Tissue Regeneration Solutions

Posted on Tue/27/JanuarySun/1/February by AZBio

PHOENIX, Jan. 27, 2026 /PRNewswire/ — BioLab Holdings, Inc., a Phoenix‑based medical manufacturer specializing in advanced wound protection technologies, has announced a strategic investment in Imbed Biosciences, Inc., the Wisconsin‑based medical device innovator behind the fully-synthetic SAM™ Antimicrobial Technology, and Microlyte®, the wound matrix based on SAM™ Technology.Continue reading→

CMS Announces Selection of Drugs for Third Cycle of Medicare Drug Price Negotiation Program, Including First-Ever Part B Drugs

Posted on Tue/27/JanuaryTue/27/January by AZBio

Negotiations Will Occur in 2026 With Negotiated Prices Effective in 2028Continue reading→

The Buzz at JPM Week 2026

Posted on Tue/27/JanuaryTue/27/January by AZBio

Each year, JPM Week in San Francisco is one of the largest gatherings of Biotech, Medtech, and Health IT innovators and investors in the world. 2026 was no exception. Tune in to this AZBioPEERS discussion to gain insights on trends shaping the year ahead for life science companies, learn about upcoming investor conferences and get tips for adjusting your fundraising strategy in today’s market.Continue reading→

‘Trojan horse’ may deliver toxic dose of copper to bacterial colonies, including drug-resistant MRSA infections

Posted on Tue/27/JanuaryTue/27/January by AZBio

A research team at the University of Arizona College of Medicine – Tucson is developing a drug that works in combination with copper to kill bacteria, including those that cause MRSA, a type of staph infection that is resistant to usual treatments. They published their results last month in mSphere.Continue reading→

Applications Open for the 2026 XLR8 PBC Cohort

Posted on Sun/25/JanuarySun/25/January by AZBio

APPLICATION DEADLINE: WEDNESDAY, FEBRUARY 18

XLR8 PBC is designed for health tech companies that are prepared to scale (abaca 6). Ideal applicants have a validated product or solution, early traction in the market, and are seeking strategic partnerships, mentorship, and investor connections to accelerate their growth. The program lasts 6 months, with two in-person sessions in Phoenix. APPLYContinue reading→

U of A expert urges for more comprehensive telehealth policy

Posted on Fri/23/JanuaryFri/23/January by AZBio

Six years after the COVID pandemic, the virtues of remote health care are clear: Allowing patients to visit with their providers via phone or video call often means better access to health care for patients, including those in rural communities and those who struggle to leave their homes.

But the laws that regulate telehealth, as it’s known, have not kept pace with its rise and demand – at least not in the form of comprehensive legislation. Since the pandemic, Congress has funded telehealth largely on a stopgap basis, temporarily extending COVID-era flexibilities more than a dozen times in the last few years. Each time, the extension provides only temporary funding to the Centers for Medicare and Medicaid Services – the nation’s largest funder of telehealth services.

The newest deadline for Congress to act on telehealth policy – the 15th deadline set on this issue since the COVID pandemic – is Jan. 30.Continue reading→